Reshma Jagsi, M.D., DPhil

“What happens in this study?
Radiation therapy is a type of treatment that uses high energy X-rays to damage the DNA of cancer cells in order to kill these cells and shrink tumors. Olaparib (LYNZPARZA®) is a type of targeted therapy called a PARP inhibitor. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. The goal of this study is to determine whether olaparib in combination with radiation therapy, the current standard of care after mastectomy and chemotherapy, will improve outcomes for patients with inflammatory breast cancer.

This is a randomized trial, which means neither the doctor nor the participant choose the study group for a patient. Instead, participants are assigned by chance to receive either radiation therapy alone or radiation therapy and olaparib.

Are you eligible?
A woman or man over the age of 18 is eligible if they have been diagnosed with inflammatory breast cancer without distant metastases, have completed neoadjuvant chemotherapy, have undergone modified radical mastectomy, and have no history of radiation therapy to the chest wall on the same side as the breast cancer. The status of this study is subject to change.

To see the most up to date information, visit clinicaltrials.gov.

What will this mean for patients?
This study may offer participants the chance to receive a new targeted therapy for inflammatory breast cancer. It will help researchers and doctors learn whether giving this drug in addition to radiation therapy works better to kill cancer cells than radiation therapy alone. Participants will contribute to cancer research that one day may help improve the treatment and outcomes for inflammatory breast cancer.

Who do I contact about this study?
Reshma Jagsi, M.D., DPhil, the Principal Investigator (PI) of this study, is a Komen Scholar and Chair of Radiation Oncology at Emory University. She is a leading expert on inflammatory breast cancer. Her research interests include understanding the mechanisms by which drugs targeting DNA damage and radiotherapy may interact to improve the efficacy of radiotherapy.

Komen connection
Reshma Jagsi, M.D., DPhil, the Principal Investigator (PI) of this study, is a Komen Scholar and Chair of Radiation Oncology at Emory University. She is a leading expert on inflammatory breast cancer. Her research interests include understanding the mechanisms by which drugs targeting DNA damage and radiotherapy may interact to improve the efficacy of radiotherapy.

SUSAN G. KOMEN BREAST CARE HELPLINE
For more information about clinical trials, please call our Breast Care Helpline at 1-877 GO KOMEN (1-877-465-6636) or email at clinicaltrialinfo@komen.org to connect with a trained specialist or oncology social worker. Our caring and trained staff provide support, education and resource referrals to help people gain a better understanding of clinical trials. Se habla español.

This information is being provided for education purposes only and does not contain all information related to this clinical study. The study status and eligibility criteria may change. If you are interested in learning if this study is right for you, please reach out to the study coordinator or your doctor for more information.

©2023 Susan G. Komen®